In some instances, smaller is better… especially when you’re looking for monstrous growth.

Big companies are big because they’re dominating forces. They’re sprawling enterprises that span the globe. But in most cases, they didn’t start out that way.

For example, last year, Amazon (Nasdaq: AMZN) became the second company ever to have a $1 trillion market cap. But the e-commerce giant began as a microcap online book seller in the 1990s.

That’s the success every microcap investor hopes to replicate.

All About Size

Now, before we go any further, let’s get something straight.

Oftentimes, there’s some confusion about what constitutes a microcap.

Most people believe it has to do with price. And it’s true that many microcaps trade for less than $1 or even $0.50. But share price has little to do with the distinction.

It actually has to do with market cap. When we use “cap” quantifiers like small, mid, large and even mega, we’re talking about stocks with market caps in specific ranges.

Generally, microcaps are companies with valuations between $50 million and $300 million. That means they’re small. And anything smaller than that falls into the category of nanocap stocks.

Top 10 Microcaps for 2020

Now, like many traders, gunslingers and speculators, I don’t shy away from microcaps or nanocaps.

They are more volatile. But they offer growth you often can’t find in any other segment of the market. That’s because many of them are still in the early stages of their growth cycle.

And the returns can be astronomical.

You don’t need to dig any deeper than Amazon or Monster Beverage Corp. (Nasdaq: MNST). These former microcaps have been two of the best-performing stocks of the last 20-plus years…

With that in mind, I wanted to focus this week on some minuscule companies that are projected to see monster revenue growth next year.

Here are 10 companies that are expecting at least quadruple-digit increases in sales in 2020…

You may notice that, once again, biotechs and biopharmaceuticals dominate the list, as they did with our small cap ranking a couple of weeks ago.

This week, biotechs snagged six of the 10 spots.

But, surprisingly, not No. 1!

At the top of our list is Workhorse Group (Nasdaq: WKHS). The microcap’s 2020 revenue is expected to skyrocket 10,085% higher!

The U.S. battery-electric aircraft and vehicle manufacturer is projected to see sales go from $810,000 to $82.5 million. That’s because it’ll actually begin selling vehicles next year.

Of course, there’s a lot of headline-snagging competition in the space – from General Motors (NYSE: GM) to Tesla (Nasdaq: TSLA). But none of them offer the kind of revenue growth Workhorse does.

At No. 2, we have our first of three biotechs in the top five, NewLink Genetics Corp. (Nasdaq: NLNK).

NewLink is expected to see revenue explode 6,233% higher from $750,000 to $47.5 million.

The company is merging with Lumos Pharma (and changing its name to that too). It’ll spend 2020 focusing its efforts on Lumos’ pediatric growth hormone deficiency treatment, ibutamoren.

Eiger BioPharmaceuticals (Nasdaq: EIGR) is also projected to see more than 6,000% revenue growth next year. Analysts are forecasting the late-stage biopharmaceutical company will see sales jump from $490,000 to more than $30 million.

And rounding out the top five, we have VolitionRx (NYSE: VNRX). The microcap is in the healthcare and diagnostics sector, like Motus GI Holdings (Nasdaq: MOTS).

Volition develops blood tests to diagnose a range of cancers and other diseases.

Motus is a medical device company. It’s working on commercialization of its Pure-Vu system, which helps facilitate the cleaning of a poorly prepared colon during a colonoscopy.

The other microcap that isn’t a biotech on this list is Cadiz (Nasdaq: CDZI). It’s a land and water resource development utility based in California. And its business is projected to boom next year as revenue is expected to grow 2,911% from $730,000 to $21.98 million.

The Amazons of Tomorrow

I always believe share price will eventually follow revenue and earnings. This is why I avidly follow and invest in high-growth stocks.

Nothing is better than gobbling up shares of a fast-growing company before it becomes a regular feature on mainstream financial media.

And though microcaps and nanocaps carry considerably more volatility than their larger brethren, these 10 with quadruple-digit revenue growth might be worth a look.

Here’s to high returns,

Matthew